Domestic companies have no choice but to silently wait until NOACs’ patent expiration
Although domestic pharmaceutical companies have tried to enter the market of novel oral anticoagulant(NOAC) generics, they have kept failed.
NOACs, which were confirmed to be used as a primary therapy with efficacy of preventing atrial fibrillation last year, have certainly become the new trend ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
